You are here: Home » PTI Stories » National » News
Business Standard

VAV Life Sciences launches phospholipid mfg plant in Maha

Press Trust of India  |  Mumbai 

One of the top phospholipid manufacturers, VAV Life Sciences inaugurated its cGMP compliant phospholipid manufacturing plant in Mirjole, at Ratnagiri in Maharashtra.

The plant is set up in considering the emerging healthcare applications of lecithins and phospholipids in functional foods, nutritional supplements, novel pharmaceuticals and cosmetics.



With the plant, the company will mark products manufactured at the factory with a 'Made in India' label and will export 80 per cent of them to North America, and Asia, a company statement said here.

The first phase of the plant is spread across 30,000 sq ft with cGMP standard facilities. The facility utilises state-of-the-art technology, which allows the production of its all-natural higher grade of phospholipids ingredient in accordance with the global industry standards. Most phospholipids are derived from nature, hence classified as GRAS (Generally Recognised as Safe) by US FDA.

Through the plant, VAV Life Sciences will be building distinct production lines for refined soya, egg and synthetic phospholipids. Ratnagiri location was the first choice to set up this plant due to its excellent infrastructure facilities, conducive business environment, suitable weather conditions and quality trained manpower.

"Phospholipids help drugs to target specific organs, tissues or even cells in the human body thus increases efficacy and eliminates toxicity. The increasing demand for green and naturally sourced ingredients, coupled with increasing consumer awareness towards healthy lifestyle, has raised demand for phospholipids. Besides, the nascent market for phospholipids is projected to reach USD 1.1 Billion by 2020 globally," VAV Life Sciences CMD Arun Kedia said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

VAV Life Sciences launches phospholipid mfg plant in Maha

One of the top phospholipid manufacturers, VAV Life Sciences inaugurated its cGMP compliant phospholipid manufacturing plant in Mirjole, at Ratnagiri in Maharashtra. The plant is set up in India considering the emerging healthcare applications of lecithins and phospholipids in functional foods, nutritional supplements, novel pharmaceuticals and cosmetics. With the plant, the company will mark products manufactured at the factory with a 'Made in India' label and will export 80 per cent of them to North America, Europe and Asia, a company statement said here. The first phase of the plant is spread across 30,000 sq ft with EU cGMP standard facilities. The facility utilises state-of-the-art technology, which allows the production of its all-natural higher grade of phospholipids ingredient in accordance with the global industry standards. Most phospholipids are derived from nature, hence classified as GRAS (Generally Recognised as Safe) by US FDA. Through the plant, VAV Life Sciences ... One of the top phospholipid manufacturers, VAV Life Sciences inaugurated its cGMP compliant phospholipid manufacturing plant in Mirjole, at Ratnagiri in Maharashtra.

The plant is set up in considering the emerging healthcare applications of lecithins and phospholipids in functional foods, nutritional supplements, novel pharmaceuticals and cosmetics.

With the plant, the company will mark products manufactured at the factory with a 'Made in India' label and will export 80 per cent of them to North America, and Asia, a company statement said here.

The first phase of the plant is spread across 30,000 sq ft with cGMP standard facilities. The facility utilises state-of-the-art technology, which allows the production of its all-natural higher grade of phospholipids ingredient in accordance with the global industry standards. Most phospholipids are derived from nature, hence classified as GRAS (Generally Recognised as Safe) by US FDA.

Through the plant, VAV Life Sciences will be building distinct production lines for refined soya, egg and synthetic phospholipids. Ratnagiri location was the first choice to set up this plant due to its excellent infrastructure facilities, conducive business environment, suitable weather conditions and quality trained manpower.

"Phospholipids help drugs to target specific organs, tissues or even cells in the human body thus increases efficacy and eliminates toxicity. The increasing demand for green and naturally sourced ingredients, coupled with increasing consumer awareness towards healthy lifestyle, has raised demand for phospholipids. Besides, the nascent market for phospholipids is projected to reach USD 1.1 Billion by 2020 globally," VAV Life Sciences CMD Arun Kedia said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

VAV Life Sciences launches phospholipid mfg plant in Maha

One of the top phospholipid manufacturers, VAV Life Sciences inaugurated its cGMP compliant phospholipid manufacturing plant in Mirjole, at Ratnagiri in Maharashtra.

The plant is set up in considering the emerging healthcare applications of lecithins and phospholipids in functional foods, nutritional supplements, novel pharmaceuticals and cosmetics.

With the plant, the company will mark products manufactured at the factory with a 'Made in India' label and will export 80 per cent of them to North America, and Asia, a company statement said here.

The first phase of the plant is spread across 30,000 sq ft with cGMP standard facilities. The facility utilises state-of-the-art technology, which allows the production of its all-natural higher grade of phospholipids ingredient in accordance with the global industry standards. Most phospholipids are derived from nature, hence classified as GRAS (Generally Recognised as Safe) by US FDA.

Through the plant, VAV Life Sciences will be building distinct production lines for refined soya, egg and synthetic phospholipids. Ratnagiri location was the first choice to set up this plant due to its excellent infrastructure facilities, conducive business environment, suitable weather conditions and quality trained manpower.

"Phospholipids help drugs to target specific organs, tissues or even cells in the human body thus increases efficacy and eliminates toxicity. The increasing demand for green and naturally sourced ingredients, coupled with increasing consumer awareness towards healthy lifestyle, has raised demand for phospholipids. Besides, the nascent market for phospholipids is projected to reach USD 1.1 Billion by 2020 globally," VAV Life Sciences CMD Arun Kedia said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22